Erytech Pharma S.A. (ERYP): Price and Financial Metrics
GET POWR RATINGS... FREE!
ERYP Stock Summary
- With a market capitalization of $24,566,694, ERYTECH PHARMA SA has a greater market value than just 9.54% of US stocks.
- Revenue growth over the past 12 months for ERYTECH PHARMA SA comes in at 448.59%, a number that bests 97.99% of the US stocks we're tracking.
- ERYTECH PHARMA SA's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -53.18%, greater than the shareholder yield of just 10.67% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to ERYTECH PHARMA SA are SONN, CANF, MEIP, PULM, and HCM.
- ERYP's SEC filings can be seen here. And to visit ERYTECH PHARMA SA's official web site, go to www.erytech.com.
ERYP Stock Price Chart Interactive Chart >
ERYP Price/Volume Stats
| Current price | $1.03 | 52-week high | $2.18 |
| Prev. close | $0.79 | 52-week low | $0.30 |
| Day low | $0.80 | Volume | 61,200 |
| Day high | $1.09 | Avg. volume | 40,435 |
| 50-day MA | $0.79 | Dividend yield | N/A |
| 200-day MA | $0.81 | Market Cap | 32.07M |
Erytech Pharma S.A. (ERYP) Company Bio
ERYTECH Pharma Société Anonyme, a clinical-stage biopharmaceutical company, develops therapies for rare forms of cancer and orphan diseases in France and internationally. The company is developing a pipeline of product candidates targeting markets with unmet medical need using its proprietary ERYCAPS platform, a technology to encapsulate therapeutic drug substances inside red blood cells. It primarily focuses on the treatment of blood cancers, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by depriving tumors of nutrients necessary for their survival. The company was founded in 2004 and is based in Lyon, France.
Latest ERYP News From Around the Web
Below are the latest news stories about ERYTECH PHARMA SA that investors may wish to consider to help them evaluate ERYP as an investment opportunity.
ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022ERYTECH Provides Business and Financial Update for the Fourth Quarter and Full Year 2022 Combination with Pherecydes announced, intending to create a global leader in extended phage therapies targeting antimicrobial resistant pathogenic bacteria Deep restructuring implemented; team size reduced by approximately 75% since start of 2022Cash and cash equivalents of €38.8 million ($41.5 million) at the end of December 2022 Cambridge, MA (U.S.) and Lyon (France), March 22, 2023 – ERYTECH Pharma (Nasd |
Monthly information related to total number of voting rights and shares composing the share capital _February 28, 2023Monthly information related to total number of voting rights and shares composing the share capital _February 28, 2023. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net |
ERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage TherapiesERYTECH and PHERECYDES Announce Proposed Combination Intending to Create Global Leader in Extended Phage Therapies Conference call and webcast in English on February 16, 2023at 8:30am EST / 02:30pm CET and in French on the same day at 12pm EST / 6pm CET Strategic combination would build on complementary expertise and capabilities of both companies to accelerate development of extended phage therapies for antimicrobial resistance (AMR), in particular via the phase II PhagoDAIR study conducted by |
Monthly information related to total number of voting rights and shares composing the share capital _January 31, 2023Monthly information related to total number of voting rights and shares composing the share capital _January 31, 2023. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net ( |
Monthly information related to total number of voting rights and shares composing the share capital _December 31, 2022Monthly information related to total number of voting rights and shares composing the share capital _December 31, 2022. Article 223-16 of general regulation of French Autorité des Marchés FinanciersLyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP)Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut (1) voting rightsTotal of net |
ERYP Price Returns
| 1-mo | 20.69% |
| 3-mo | 157.56% |
| 6-mo | 71.38% |
| 1-year | -45.79% |
| 3-year | -80.00% |
| 5-year | N/A |
| YTD | 212.03% |
| 2022 | -85.95% |
| 2021 | -74.54% |
| 2020 | 25.15% |
| 2019 | 8.94% |
| 2018 | -69.26% |
Continue Researching ERYP
Want to see what other sources are saying about Erytech Pharma SA's financials and stock price? Try the links below:Erytech Pharma SA (ERYP) Stock Price | Nasdaq
Erytech Pharma SA (ERYP) Stock Quote, History and News - Yahoo Finance
Erytech Pharma SA (ERYP) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...